BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma
暂无分享,去创建一个
Sohrab P Shah | Jiarui Ding | Janine Senz | C Blake Gilks | David G Huntsman | Jessica N McAlpine | S. Shah | Jiarui Ding | D. Huntsman | M. Köbel | J. Senz | S. Kalloger | C. Gilks | J. McAlpine | L. Prentice | B. Nelson | K. Milne | Brad H Nelson | Steve E Kalloger | Martin Köbel | Katy Milne | H. Porter | Leah M Prentice | Henry Porter | Sohrab P. Shah | Sohrab P. Shah
[1] Gerd Ritter,et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[2] B. Gullberg,et al. Prognostic factors in malignant epithelial ovarian tumors. , 1983, Gynecologic oncology.
[3] A. D’Andrea,et al. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway , 2006, Molecular Cancer Therapeutics.
[4] P. Spellman,et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities , 2008, BMC Cancer.
[5] R. Buller,et al. Frequency of BRCA1 dysfunction in ovarian cancer. , 2002, Journal of the National Cancer Institute.
[6] P. Tassone,et al. Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo , 2009, Cancer biology & therapy.
[7] D. Katsaros,et al. Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential , 2006, Cancer.
[8] R. Ozols,et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Jorge S. Reis-Filho,et al. Resistance to therapy caused by intragenic deletion in BRCA2 , 2008, Nature.
[10] David D. L. Bowtell,et al. The genesis and evolution of high-grade serous ovarian cancer , 2010, Nature Reviews Cancer.
[11] J. Boyd,et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. , 2000, JAMA.
[12] R. L. Baldwin,et al. Improved survival in women with BRCA‐associated ovarian carcinoma , 2003, Cancer.
[13] E. Venkatraman,et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. , 2001, Gynecologic oncology.
[14] Ryan D. Morin,et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.
[15] D. Huntsman,et al. Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. , 2010, Gynecologic oncology.
[16] I. Shih,et al. Are All Pelvic (Nonuterine) Serous Carcinomas of Tubal Origin? , 2010, The American journal of surgical pathology.
[17] B. Nelson,et al. The impact of T‐cell immunity on ovarian cancer outcomes , 2008, Immunological reviews.
[18] K. Offit,et al. Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] A. Ayhan,et al. Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects , 2006, International Journal of Gynecologic Cancer.
[20] D. Levine,et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? , 2007, Gynecologic oncology.
[21] M. Kattan,et al. Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Soldano Ferrone,et al. HLA Class I Antigen Processing Machinery Component Expression and Intratumoral T-Cell Infiltrate as Independent Prognostic Markers in Ovarian Carcinoma , 2008, Clinical Cancer Research.
[23] R. Eeles,et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] G. Mills,et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Lalit Kumar,et al. Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer , 2006, Indian Journal of Medical and Paediatric Oncology.
[26] S. Leung,et al. Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies , 2008, PLoS medicine.
[27] Barry Rosen,et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. , 2006, Journal of the National Cancer Institute.
[28] R. Weichselbaum,et al. The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin* , 2000, The Journal of Biological Chemistry.
[29] R. Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[30] G. Kenter,et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.
[31] R. Eeles,et al. Dramatic response to platinum in a patient with cancer with a germline BRCA2 mutation. , 2009, Clinical oncology (Royal College of Radiologists (Great Britain)).
[32] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[33] D. Katsaros,et al. Weekly Low-Dose Paclitaxel as Maintenance Treatment in Patients With Advanced Ovarian Cancer Who Had Microscopic Residual Disease at Second-Look Surgery After 6 Cycles of Paclitaxel/Platinum-Based Chemotherapy: Results of an Open Noncomparative Phase 2 Multicenter Italian Study (After-6 Protocol 2) , 2009, International Journal of Gynecologic Cancer.
[34] L. Shulman,et al. A Systematic Genetic Assessment of 1,433 Sequence Variants of Unknown Clinical Significance in the BRCA1 and BRCA2 Breast Cancer–Predisposition Genes , 2008 .
[35] A. Reuss,et al. Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian Cancer , 2010, International Journal of Gynecologic Cancer.
[36] Matt van de Rijn,et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss , 2009, Modern Pathology.
[37] D. Levine,et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. , 2006, Gynecologic oncology.
[38] S. Cannistra. BRCA-1 in Sporadic Epithelial Ovarian Cancer: Lessons Learned from the Genetics of Hereditary Disease , 2007, Clinical Cancer Research.
[39] Nhu Le,et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. , 2008, Human pathology.
[40] Dongxia Gao,et al. Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors , 2009, PloS one.
[41] Carlos Caldas,et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary , 2010, The Journal of pathology.
[42] Hans W. Nijman,et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer , 2008, Cancer Immunology, Immunotherapy.
[43] George Coukos,et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.
[44] R. Buller,et al. Inactivation of BRCA1 and BRCA2 in ovarian cancer. , 2002, Journal of the National Cancer Institute.
[45] F. Couch,et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers , 2008, Nature.
[46] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[47] S. Powell,et al. Therapeutic exploitation of tumor cell defects in homologous recombination. , 2008, Anti-cancer agents in medicinal chemistry.
[48] F. Couch,et al. Edinburgh Research Explorer Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma , 2022 .
[49] Alan Ashworth,et al. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. , 2002, Trends in molecular medicine.
[50] B. Monk,et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] P. Johnston,et al. BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy , 2007, Clinical Cancer Research.
[52] N. Curtin,et al. PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine , 2011, BJOG : an international journal of obstetrics and gynaecology.
[53] W. Foulkes. BRCA1 and BRCA2: Chemosensitivity, Treatment Outcomes and Prognosis , 2005, Familial Cancer.
[54] W. Cliby,et al. Aggressive Surgical Effort and Improved Survival in Advanced-Stage Ovarian Cancer , 2006, Obstetrics and gynecology.
[55] C. Waes,et al. Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines. , 2007, Cancer letters.
[56] Ashok R Venkitaraman,et al. Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. , 2009, Annual review of pathology.
[57] P. Gimotty,et al. Intraepithelial T cells and tumor proliferation , 2009, Cancer.
[58] A. Reuss,et al. The biological and clinical value of p53 expression in pelvic high‐grade serous carcinomas , 2010, The Journal of pathology.
[59] P. Karran,et al. DNA double strand break repair in mammalian cells. , 2000, Current opinion in genetics & development.
[60] L. Shulman. “BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated With BRCA1 and BRCA2 Mutations , 2009 .
[61] Kevin P. Murphy,et al. SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors , 2010, Bioinform..
[62] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[63] H. Mackay,et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. , 2011, The Lancet. Oncology.
[64] M. Morgan,et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. , 1996, The New England journal of medicine.
[65] M. Pestrin,et al. Using specific cytotoxics with a targeted mind. , 2007, Breast.